AMG 531: an investigational thrombopoiesis-stimulating peptibody.
Thrombopoietin (TPO) regulates megakaryopoiesis and the generation of platelets. Recombinant TPO has been investigated in clinical studies for use in thrombocytopenia with limited success. A new peptibody, AMG 531, has been shown to increase platelet counts in preclinical and Phase 1 and Phase 2 studies and to be generally safe and tolerable in those studies.
Nichol
Janet L
JL
Amgen, Inc., Thousand Oaks, California 91320, USA. jnichol@amgen.com
D000818:Animals; D002352:Carrier Proteins / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010919:Placebos; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy* / Q000276:immunology; D016032:Randomized Controlled Trials as Topic; D011961:Receptors, Fc / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins; D034061:Thrombopoiesis / Q000187:drug effects* / Q000276:immunology; D013926:Thrombopoietin
D002352:Carrier Proteins; D010919:Placebos; D011961:Receptors, Fc; D011993:Recombinant Fusion Proteins; D013926:Thrombopoietin; C488777:romiplostim